NCT00635258COMPLETEDanonymous

Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.

Sponsor

Source record

Centro Ginecologia y Obstetricia.

Phase

Source record

Not classified

Modality

AI-normalized

small molecule

Target

AI-normalized

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Indication / condition

AI-normalized

Pregnancy

Intervention

Source record

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Source & freshness

Source record

NCT ID

NCT00635258

Original source

ClinicalTrials.gov

Source last updated

Mar 13, 2008

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00635258

Title

Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.

Sponsor

Centro Ginecologia y Obstetricia.

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Pregnancy, Embryo Implantation

Condition normalized

Pregnancy, Embryo Implantation

Modality raw

small molecule

Modality normalized

small molecule

Target raw

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Target normalized

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Interventions

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Public preview

Source record

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00635258

Status

COMPLETED

Phase

N/A

Sponsor

Centro Ginecologia y Obstetricia.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 13, 2008

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00635258

Indication

Pregnancy

Modality

small molecule

Target

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Intervention

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.